BioMarin Pharmaceutical: A Volatile But Growing Trajectory
…
64,630$
-2,86%
Echtzeit-Aktienkurs Biomarin Pharmaceutical Inc.
Bid:
Ask:
Nachrichten zur Biomarin Pharmaceutical Inc. Aktie
BioMarin Pharmaceutical-Aktienanalyse: JPMorgan reduziert Kursziel
New York (www.aktiencheck.de) - BioMarin Pharmaceutical-Aktienanalyse von JPMorgan:
JPMorgan-Analystin Jessica Fye hat das Kursziel für BioMarin Pharmaceutical (ISIN: US09061G1013, WKN: 924801,…
BioMarin Pharmaceutical: Kursziel 110 USD
New York (www.aktiencheck.de) - Rating-Update:
Olivia Brayer, Analystin von Cantor Fitzgerald, stuft die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN:…
BioMarin Pharmaceutical: Kursziel angehoben
Minneapolis (www.aktiencheck.de) - Rating-Update:
Die Analysten von Piper Sandler stufen die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN 924801, Ticker-Symbol:…
BioMarin Pharmaceutical: Kursziel gekappt
Charlotte, NC (www.aktiencheck.de) - Rating-Update:
Die Analysten von Truist bewerten die Aktie von BioMarin Pharmaceutical Inc. (ISIN: US09061G1013, WKN: 924801, Ticker-Symbol:…
Zacks.com featured highlights include Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo
Wolverine World Wide, BioMarin Pharmaceutical, Datadog, Progressive and Klaviyo are part of the Zacks Screen of the Week article.…
BioMarin Pharmaceutical Inc. (BMRN) Q2 2024 Earnings Call Transcript
…
BioMarin Pharmaceutical Q2 2024 Earnings Preview
…
BioMarin Pharmaceutical: Steady Performer Scheduling Its Big Reveal In 09/2024
…
BioMarin Pharmaceutical: Kursziel erhöht
San Francisco (www.aktiencheck.de) - Rating-Update:
Die Einschätzung von Mohit Bansal, Analyst von Wells Fargo Advisors, für die Aktie von BioMarin Pharmaceutical…
BioMarin Pharmaceutical, Inc. (BMRN) Q1 2024 Earnings Call Transcript
…
BioMarin Pharmaceutical Inc. 2024 Q1 - Results - Earnings Call Presentation
…
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the…
GMAB: 3 Biotech Stocks Gaining Altitude and Interest
This year, the biotech industry anticipates a resurgence with increased M&A, FDA approvals, and AI-driven innovations. Given the industry’s rosy…
BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
…